A multicenter, add-on randomized controlled trial of low-dose D-serine for negative and cognitive symptoms of schizophrenia

Journal of Clinical Psychiatry

Volumn 73, Issue 6, 2012, Pages

  Weiser, Mark ^a,b   Heresco Levy, Uriel ^c   Davidson, Michael ^a,b   Javitt, Daniel C ^l   Werbeloff, Nomi ^a   Gershon, Ari A ^a   Abramovich, Yehuda ^d   Amital, Daniela ^d   Doron, Adiel ^e   Konas, Shai ^f   Levkovitz, Yehiel ^g   Liba, David ^h   Teitelbaum, Alexander ⁱ   Mashiach, Mordechai ^j   Zimmerman, Yosef ^g,k  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY   (Israel)

^d NESS ZIONA MENTAL HEALTH CENTER   (Israel)

^e LEV HASHARON MENTAL HEALTH CENTER   (Israel)

^f GEHA MENTAL HEALTH CENTER   (Israel)

^g SHALVATA MENTAL HEALTH CENTER   (Israel)

^h Mazra Mental Health Center   (Israel)

ⁱ Jerusalem Mental Health Center Ezrath Nashim   (Israel)

^j ABARBANEL MENTAL HEALTH CENTER   (Israel)

^k NEW YORK UNIVERSITY   (United States)

^l NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO SERINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PLACEBO; SERINE;

ADD ON THERAPY; ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ASSESSMENT TOOL; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT AND TREATMENT RESEARCH TO IMPROVE COGNITION AND SCHIZOPHRENIA; MOUTH ULCER; MULTICENTER STUDY; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; PLACEBO EFFECT; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84863550158     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m07031     Document Type: Article

References (57)

1. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301-1308. PubMed
2. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199-214. doi:10.101/archpsyc.194.03950303504 PubMed (Pubitemid 24081509)
3. Krystal JH, Perry EB Jr, Gueorguieva R, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry. 2005;62(9):985-994. doi:10.101/archpsyc.62.9.985 PubMed
4. Luby ED, Gottlieb JS, Cohen BD, et al. Model psychoses and schizophrenia. Am J Psychiatry. 1962;119:61-67. PubMed
5. Umbricht D, Schmid L, Koller R, et al. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry. 2000;57(12):1139-1147. doi:10.101/archpsyc.57.12.139 PubMed
6. Hahn CG, Wang HY, Cho DS, et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med. 2006;12(7):824-828. doi:10.1038/nm1418 PubMed
7. Javitt DC, Liederman E, Cienfuegos A, et al. Panmodal processing imprecision as a basis for dysfunction of transient memory storage systems in schizophrenia. Schizophr Bull. 1999;25(4):763-775. PubMed (Pubitemid 30013558)
8. Heresco-Levy U, Ermilov M, Lichtenberg P, et al. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry. 2004;55(2):165-171. doi:10.1016/S06-323(03)0707-8 PubMed (Pubitemid 38367720)
9. Heresco-Levy U, Javitt DC, Ermilov M, et al. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 1996;169(5):610-617. doi:10.192/bjp.169.5.610 PubMed
10. Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 1999;56(1):29-36. doi:10.101/archpsyc.56.1.29 PubMed (Pubitemid 29055047)
11. Tsai GE, Yang P, Chang YC, et al. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2006;59(3):230-234. doi:10.1016/j.biopsych.205.06.032 PubMed (Pubitemid 43208969)
12. Tsai G, Yang P, Chung LC, et al. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998;44(11):1081-1089. doi:10.1016/S06-323(98)0279-0 PubMed (Pubitemid 28547143)
13. Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry. 2005;57(6):577-585. doi:10.1016/j.biopsych.204. 12.037 PubMed (Pubitemid 40409697)
14. Evins AE, Amico E, Posever TA, et al. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res. 2002;56(1-2):19-23. doi:10.1016/S0920-964(01)020-1 PubMed (Pubitemid 34655463)
15. Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999;56(1):21-27. doi:10.101/archpsyc.56.1.21 PubMed (Pubitemid 29055046)
16. Goff DC, Tsai G, Manoach DS, et al. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 1995;152(8):1213-1215. PubMed
17. Heresco-Levy U, Ermilov M, Shimoni J, et al. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry. 2002;159(3):480-482. doi:10.176/api.ajp.159.3. 480 PubMed (Pubitemid 34184748)
18. van Berckel BN, Hijman R, van der Linden JA, et al. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry. 1996;40(12):1298-1300. doi:10.1016/S06-323(96)031-3 PubMed (Pubitemid 27006415)
19. Lane HY, Chang YC, Liu YC, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005;62(11):1196-1204. doi:10.101/archpsyc.62.1.196 PubMed
20. Tsai G, Lane HY, Yang P, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2004;55(5):452-456. doi:10.1016/j.biopsych.203. 09.012 PubMed (Pubitemid 38338531)
21. Duncan EJ, Szilagyi S, Schwartz MP, et al. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res. 2004;71(2-3):239-248. doi:10.1016/j.schres.204.03.013 PubMed (Pubitemid 39330502)
22. Goff DC, Herz L, Posever T, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl). 2005;179(1):144-150. doi:10.107/s0213-04-2032-2 PubMed (Pubitemid 40576701)
23. van Berckel BN, Evenblij CN, van Loon BJ, et al. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology. 1999;21(2):203-210. doi:10.1016/S0893-13X(9)014-7 PubMed
24. Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164(10):1593-1602. doi:10.176/api.ajp.207.06081358 PubMed (Pubitemid 350069740)
25. Bauer D, Hamacher K, Bröer S, et al. Preferred stereoselective brain uptake of d-serine-a modulator of glutamatergic neurotransmission. Nucl Med Biol. 2005;32(8):793-797. doi:10.1016/j.nucmedbio.205.07.04 PubMed (Pubitemid 41505312)
26. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry. 1982;39(7):784-788. doi:10.101/archpsyc.1982. 0429070205 PubMed (Pubitemid 12090301)
27. Green MF, Nuechterlein KH, Kern RS, et al. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry. 2008;165(2):221-228. doi:10.176/api.ajp.207.0701089 PubMed (Pubitemid 351704522)
28. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). New York, NY: Biometrics Research, New York State Psychiatric Institute; 1997.
29. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. PubMed (Pubitemid 18039085)
30. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. Five-factor model of schizophrenia: initial validation. J Nerv Ment Dis. 1994;182(11):631-638. doi:10.1097/05053-19410-06 PubMed (Pubitemid 24369237)
31. Csernansky JG, Mahmoud R, Brenner R; Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346(1):16-22. doi:10.1056/NEJMoa02028 PubMed (Pubitemid 34438915)
32. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976: 218-222.
33. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;45(S212):11-19. doi:10.1/j.160-047.1970.tb0206. x PubMed
34. Fann WE, Stafford JR, Malone RL, et al. Clinical research techniques in tardive dyskinesia. Am J Psychiatry. 1977;134(7):759-762. PubMed (Pubitemid 8137213)
35. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand suppl. 1987;76(s334):1-100. doi:10.1/j.160-047.1987.tb1056.x PubMed (Pubitemid 17115352)
36. Kern RS, Nuechterlein KH, Green MF, et al. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry. 2008;165(2):214-220. doi:10.176/api.ajp.207.0701043 PubMed (Pubitemid 351704521)
37. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203-213. doi:10.176/api.ajp.207.0701042 PubMed (Pubitemid 351704520)
38. Blair JR, Spreen O. Predicting premorbid IQ: a revision of the national adult reading test. Clin Neuropsychol. 1989;3(2):129-136.
39. Keefe RS, Goldberg TE, Harvey PD, et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68(2-3):283-297. doi:10.1016/j.schres.203.09.01 PubMed (Pubitemid 38526150)
40. War Department. Manual of Directions and Scoring. In: Army Individual Test Battery. Washington, DC: War Department, Adjutant General's Office. 1944.
41. Cornblatt BA, Risch NJ, Faris G, et al. The Continuous Performance Test, identical pairs version (CPT-IP), 1: new findings about sustained attention in normal families. Psychiatry Res. 1988;26(2):223-238. doi:10.1016/0165-1781(8) 9076-5 PubMed
42. Gold JM, Carpenter C, Randolph C, et al. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry. 1997;54(2):159-165. doi:10.101/archpsyc.197.0183014071013 PubMed (Pubitemid 27074304)
43. Wechsler D. Wechsler Memory Scale. San Antonio, TX: The Psychological Corporation; 1997.
44. Brandt J, Benedict RHB. The Hopkins Verbal Learning Test-Revised. Odessa, FL: Psychological Assessment Resources; 2001.
45. Benedict RHB. Brief Visuospatial Memory Test-Revised. Odessa, FL: Psychological Assessment Resources; 1997.
46. White T, Stern RA. Neuropsychological Assessment Battery. Lutz, FL: Psychological Assessment Resources; 2003.
47. Mayer JD, Salovey P, Caruso DR. Mayer-Salovey-Caruso Emotional Intelligence Test. Toronto, Canada: MHS Publishers; 2002.
48. Hariharan M, Naga S, VanNoord T. Systematic approach to the development of plasma amino acid analysis by high-performance liquid chromatography with ultraviolet detection with precolumn derivatization using phenyl isothiocyanate. J Chromatogr. 1993;621(1):15-22. doi:10.1016/0378-4347(93)8071-B PubMed (Pubitemid 23347820)
49. Muthén B. Latent variable analysis: growth mixture modeling and related techniques for longitudinal data. In: Kaplan D, ed. The SAGE Handbook of Quantitative Methodology for the Social Sciences. Newbury Park, CA: SAGE Publications, Inc; 2004:345-368.
50. Muthén B, Muthén LK. Integrating person-centered and variable-centered analyses: growth mixture modeling with latent trajectory classes. Alcohol Clin Exp Res. 2000;24(6):882-891. doi:10.1/j.1530-027.20. tb02070.x PubMed (Pubitemid 30421740)
51. Kantrowitz JT, Malhotra AK, Cornblatt B, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res. 2010;121(1-3):125-130. doi:10.1016/j.schres.2010.05.012 PubMed
52. Kemp AS, Schooler NR, Kalali AH, et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 2010;36(3):504-509. doi:10.1093/schbul/sbn10 PubMed
53. Lane HY, Lin CH, Huang YJ, et al. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol. 2010;13(4):451-460. doi:10.1017/S1461457090939 PubMed
54. Lane HY, Huang CL, Wu PL, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry. 2006;60(6):645-649. doi:10.1016/j.biopsych.206. 04.05 PubMed
55. Lane HY, Liu, YC, Huang, CL, et al. Sarcosine (N-Methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2008;63 (1);9-12.
56. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13(9):1102-1107. doi:10.1038/nm1632 PubMed (Pubitemid 47517511)
57. Umbricht D, Yoo K, Youssef E, et al. Glycine Transporter Type 1 (GLYT1) Inhibitor RG1678: Positive Results of the Proof-of-Concept Study for the Treatment of Negative Symptoms in Schizophrenia. Paper presented at: American College of Neuropsychopharmacology 49th Annual Meeting; December 5-9, 2010; Miami Beach, FL. Poster Session III:49.